Becton Dickinson

Tweet this page
<
2016
2017
2018
2019
2020
2021
2022
2023
2024
>
Registration as it was on 27 Feb 2024
How to read and use this data card.
Download this datacard
The following entries are flagged as duplicates of this organisation: 193042016026-06

Overview

Lobbying Costs

400,000€ - 499,999€

Financial year: Oct 2022 - Sep 2023

Lobbyists (Full time equivalent)

1 Fte (2)

Lobbyists with EP accreditation

1

High-level Commission meetings

0

Lobbying Costs over the years

  • Info

    Becton Dickinson   (BD)

    EU Transparency Register

    196359321438-80 First registered on 19 Apr 2016

    Goals / Remit

    BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance cellular studies and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, optimize respiratory care and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 45,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health.

    Main EU files targeted

    Patient Safety, including HAI's, AMR and medication management.
    MDR & IVDR.
    Occupational safety and health of healthcare staff.
    Healthcare efficiency.
    Environmental safety and regulation, including REACH and the RoHS.
    EU Public Procurement Directive.
    The Cross Border Health Directive.
    HTA Network.
    e-health.
    Health screening and early diagnosis.
    Digitalisation of medication management
    EU Pharma strategy
    Europe´s Beating Cancer Plan
    Digital strategy
    Women's health and cancer.
    Health research
    EU4HEALTH

    Address

    Head Office
    Becton, Dickinson and Company 1 Becton Drive Franklin Lakes, New Jersey 07417-1880
    New Jersey NJ 07417-188
    UNITED STATES
    EU Office
    Sàrl Terre Bonne Park – A4 Route de Crassier
    Eysins 1262
    SWITZERLAND

    Website

    http://www.bd.com/

  • People

    Total lobbyists declared

    2

    Employment timeLobbyists
    50%2

    Lobbyists (Full time equivalent)

    1

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    1 accreditations were / are live (in bold) for the selected state of 02 Jan 2025

    Name Start date End Date
    Jakub HODEK 20 Sep 2024 20 Sep 2025

    Complementary Information

    None declared

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Companies & groups

  • Networking

    Affiliation

    MedTech Europe
    European Alliance for Access to Safe Medicines (EAASM)
    European Cancer Organization (ECCO)
    Federation of European Academies of Medicine (FEAM)
    ALL-CAN

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Oct 2022 - Sep 2023

    Lobbying costs for closed financial year

    400,000€ - 499,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    None declared

    Intermediaries for current year

    None declared

    Closed year Costs

    400,000€ - 499,999€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    N/A

    Communication activities

    Support of relevant activities undertaken by MedTech Europe
    Support of the following activities:
    Protection of healthcare workers from hazardous drugs exposure risks through European Biosafety Network
    Surgical Site Infections and the importance of appropriate skin antisepsis : Public Policy Recomendations document developed by experts and presented in the European Parliament in 2020
    Global Sepsis Alliance meeting in Brussels presenting the European Sepsis Alliance organization and developing awareness
    The role of rapid diagnostics in AMR prevention:policy document developed by experts and presented in the European Parliament
    MDR and safety clauses interpretation: support activities and meetings around clarification of safety clauses in MDR through European Biosafety Network
    Medication errors prevention : supporting ECAMET project through EAASM
    Medicines shortages prevention and management in healthcare providers
    Participation in Structured Dialogue led by E. Commission on medicines shortages
    Support inclusion of patient safety in Europe´s Beating Cancer Plan through Health First Europe initiatives
    Support recommendations of CAUTI Prevention by scientific associations and Health First Europe
    Support of European Biosafety Network white papers and meetings on needle stick injuries, hazardous drugs , impact of anaesthetic gases in the environment and impact on mental health of healthcare workers from adverse events
    Support EHMA and ENSH to advocate for digitalisation of medication management in EU Hospitals

    Other activities

    None declared

  • Meetings

    Meetings

    None declared

Download this datacard